case_images: PMC11818212_01
case_images: Toxic epidermal necrolysis clinical spectrum. (A-D): exanthematous rash. Lesions start on the face and thorax before spreading to other areas and are symmetrically distributed. Early lesions typically begin with ill-defined, coalescing, erythematous macules; (E-H): extensive, sheet-like detachment and erosions, and Nikolsky sign is present.
case_images: ijms-26-01374-g001.jpg
case_images: PMC11818212_01_ijms-26-01374-g001.jpg
case_images: ijms-26-01374-f001
case_images: The patient presented with a skin rash and erythema that was neither pruritic nor painful (Figure 1).
case_images: Expression profile of evaluated cytokines. Figure shows the expression level of a 13-citokine panel for the patient with toxic epidermal necrolysis (TEN) and concurrent COVID-19, and for his parents, grouped by immune response in which they participate (A); and according with their status of overexpression and underexpression profile (B). Expression levels were calculated by quantitative real-time polymerase chain reaction by using GAPDH as endogenous control and RNA of peripheral blood mononuclear cell obtained from healthy controls (with negative qRT-PCR for SARS-CoV-2) as calibrator.
case_images: ijms-26-01374-g002.jpg
case_images: PMC11818212_01_ijms-26-01374-g002.jpg
case_images: ijms-26-01374-f002
case_images: The obtained results are displayed in Figure 2A,B.